Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
AZACTAM |
| Manufacturer |
|
Elan Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Monobactam. |
| Generic Name |
|
Aztreonam 500mg, 1g, 2g; for IM or IV inj after reconstitution; sodium-free. |
| Indications |
|
Susceptible bacterial infections, including septicemia, lower respiratory tract, complicated or uncomplicated urinary tract, skin and skin structure, gynecologic, intraabdominal. Surgical adjunct. |
| Children |
|
<9 months: not recommended. Not for septicemia or certain skin and skin structure infections; see literature. 9 months–16 years (normal renal function only): Urinary tract, lower respiratory tract, intraabdominal, gynecologic infections: mild-to-moderate: 30mg/kg IV every 8 hours; moderate-to-severe: 30mg/kg IV every 6–8 hours; max 120mg/kg/day. May need higher dose in patients with cystic fibrosis. |
| Adults |
|
UTI: 500mg–1g every 8–12 hours. Other infections: moderately severe: 1–2g every 8–12 hours. Severe: 2g every 6–8 hours. Max 1g/dose IM. Renal impairment (CrCl 10–30mL/min): Halve dose after loading dose; CrCl <10mL/min: see literature. |
| Precautions |
|
Penicillin, cephalosporin, carbapenem, or other allergy. Renal or hepatic impairment. Monitor renal function in prolonged use or with high doses. Elderly. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
May potentiate nephrotoxicity of concomitant aminoglycosides. Avoid concomitant β-lactamase-inducing drugs (e.g., cefoxitin, imipenem). |
| Adverse Reactions |
|
Local reactions (e.g., phlebitis, discomfort), GI upset, rash, anaphylaxis, blood dyscrasias, elevated liver enzymes or serum creatinine. |
| How Supplied |
|
Single-dose vials—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
